Compare Indoco Remedies with Edelweiss Financial - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

INDOCO REMEDIES vs EDELWEISS FINANCIAL - Comparison Results

INDOCO REMEDIES     Change

Indoco Remedies is engaged in the manufacturing and marketing of formulations and active pharmaceutical ingredients (APIs) for domestic as well as the international markets. The company's focus areas include anti-infective, respiratory, anti-diabetic... More

EDELWEISS FINANCIAL 
   Change

Edelweiss is among the larger institutional brokerage firms in India, with a strong domestic investment-banking business. It has a good market share in the institutional broking, and strong presence in derivatives. While its strengths remain in priva... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    INDOCO REMEDIES EDELWEISS FINANCIAL INDOCO REMEDIES/
EDELWEISS FINANCIAL
 
P/E (TTM) x 120.8 8.3 1,447.4% View Chart
P/BV x 2.0 1.1 177.5% View Chart
Dividend Yield % 0.7 1.4 48.0%  

Financials

 INDOCO REMEDIES   EDELWEISS FINANCIAL
EQUITY SHARE DATA
    INDOCO REMEDIES
Mar-18
EDELWEISS FINANCIAL
Mar-18
INDOCO REMEDIES/
EDELWEISS FINANCIAL
5-Yr Chart
Click to enlarge
High Rs317309 102.6%   
Low Rs178157 113.6%   
Sales per share (Unadj.) Rs113.193.7 120.6%  
Earnings per share (Unadj.) Rs4.59.7 45.9%  
Cash flow per share (Unadj.) Rs11.810.9 108.0%  
Dividends per share (Unadj.) Rs1.001.35 74.1%  
Dividend yield (eoy) %0.40.6 69.7%  
Book value per share (Unadj.) Rs73.272.9 100.5%  
Shares outstanding (eoy) m92.15915.50 10.1%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x2.22.5 88.1%   
Avg P/E ratio x55.524.0 231.4%  
P/CF ratio (eoy) x21.021.3 98.4%  
Price / Book Value ratio x3.43.2 105.7%  
Dividend payout %22.413.9 161.2%   
Avg Mkt Cap Rs m22,830213,403 10.7%   
No. of employees `0005.510.1 54.3%   
Total wages/salary Rs m2,20913,549 16.3%   
Avg. sales/employee Rs Th1,910.18,536.6 22.4%   
Avg. wages/employee Rs Th405.01,347.9 30.0%   
Avg. net profit/employee Rs Th75.5885.5 8.5%   
INCOME DATA
Net Sales Rs m10,41985,810 12.1%  
Other income Rs m47376 12.5%   
Total revenues Rs m10,46686,186 12.1%   
Gross profit Rs m1,34950,218 2.7%  
Depreciation Rs m6771,117 60.6%   
Interest Rs m23535,295 0.7%   
Profit before tax Rs m48414,182 3.4%   
Minority Interest Rs m0278 0.0%   
Prior Period Items Rs m039 0.0%   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m725,599 1.3%   
Profit after tax Rs m4128,901 4.6%  
Gross profit margin %12.958.5 22.1%  
Effective tax rate %15.039.5 37.9%   
Net profit margin %4.010.4 38.1%  
BALANCE SHEET DATA
Current assets Rs m5,373385,999 1.4%   
Current liabilities Rs m4,157260,489 1.6%   
Net working cap to sales %11.7146.3 8.0%  
Current ratio x1.31.5 87.2%  
Inventory Days Days68689 9.8%  
Debtors Days Days73112 65.2%  
Net fixed assets Rs m6,2447,538 82.8%   
Share capital Rs m184916 20.1%   
"Free" reserves Rs m6,56665,791 10.0%   
Net worth Rs m6,75066,706 10.1%   
Long term debt Rs m1,233273,061 0.5%   
Total assets Rs m12,363635,135 1.9%  
Interest coverage x3.11.4 218.2%   
Debt to equity ratio x0.24.1 4.5%  
Sales to assets ratio x0.80.1 623.8%   
Return on assets %5.27.0 75.2%  
Return on equity %6.113.3 45.7%  
Return on capital %9.014.7 61.5%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m3,762190 1,982.9%   
Fx outflow Rs m1,14357 2,019.1%   
Net fx Rs m2,619133 1,967.5%   
CASH FLOW
From Operations Rs m1,227-111,375 -1.1%  
From Investments Rs m-1,360-23,283 5.8%  
From Financial Activity Rs m-388148,346 -0.3%  
Net Cashflow Rs m-52113,508 -3.9%  

Share Holding

Indian Promoters % 59.2 37.3 158.7%  
Foreign collaborators % 0.0 0.1 -  
Indian inst/Mut Fund % 12.5 0.0 -  
FIIs % 6.0 21.1 28.4%  
ADR/GDR % 0.0 0.0 -  
Free float % 22.4 41.5 54.0%  
Shareholders   12,805 134,647 9.5%  
Pledged promoter(s) holding % 0.0 52.2 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare INDOCO REMEDIES With:   KOTHARI PRODUCTS  INGERSOLL RAND  FINOLEX INDUSTRIES  INDIABULLS FIN. SER.  STC INDIA  



Today's Market

Indian Indices Witness Selling, Key Q2FY20 Results, and Top Cues in Focus Today(Pre-Open)

India share markets ended their day deep in the red yesterday. At the closing bell yesterday, the BSE Sensex stood lower by 334 points (down 0.9%).

Related Views on News

INDOCO REMEDIES Announces Quarterly Results (1QFY20); Net Profit Up 118.1% (Quarterly Result Update)

Aug 14, 2019 | Updated on Aug 14, 2019

For the quarter ended June 2019, INDOCO REMEDIES has posted a net profit of Rs 22 m (up 118.1% YoY). Sales on the other hand came in at Rs 3 bn (up 16.2% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

INDOCO REMEDIES Announces Quarterly Results (4QFY19); Net Profit Down 43.3% (Quarterly Result Update)

Jun 6, 2019 | Updated on Jun 6, 2019

For the quarter ended March 2019, INDOCO REMEDIES has posted a net profit of Rs 116 m (down 43.3% YoY). Sales on the other hand came in at Rs 3 bn (down 6.5% YoY). Read on for a complete analysis of INDOCO REMEDIES's quarterly results.

EDELWEISS FINANCIAL Announces Quarterly Results (4QFY19); Net Profit Down 0.8% (Quarterly Result Update)

May 16, 2019 | Updated on May 16, 2019

For the quarter ended March 2019, EDELWEISS FINANCIAL has posted a net profit of Rs 2 bn (down 0.8% YoY). Sales on the other hand came in at Rs 29 bn (up 12.6% YoY). Read on for a complete analysis of EDELWEISS FINANCIAL's quarterly results.

INDOCO REMEDIES 2017-18 Annual Report Analysis (Annual Result Update)

Mar 28, 2019 | Updated on Mar 28, 2019

Here's an analysis of the annual report of INDOCO REMEDIES for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of INDOCO REMEDIES. Also includes updates on the valuation of INDOCO REMEDIES.

EDELWEISS FINANCIAL Announces Quarterly Results (3QFY19); Net Profit Up 9.2% (Quarterly Result Update)

Jan 25, 2019 | Updated on Jan 25, 2019

For the quarter ended December 2018, EDELWEISS FINANCIAL has posted a net profit of Rs 3 bn (up 9.2% YoY). Sales on the other hand came in at Rs 28 bn (up 34.1% YoY). Read on for a complete analysis of EDELWEISS FINANCIAL's quarterly results.

More Views on News

Most Popular

My 3 Best Small-cap Stocks to Get Rich in this Market Rebound(Profit Hunter)

Oct 14, 2019

This is once in a decade opportunity to make a killing from smallcap rebound.

Buy these 3 Stocks for Rebound Riches

Oct 18, 2019

Equitymaster's smallcap guru and editor of Hidden Treasure, Richa Agarwal, talks to us about the rebound in the stock market, and the best stocks to profit from it. Listen in...

Two Stocks to Buy in the Great Indian Festival(Profit Hunter)

Oct 11, 2019

Discounts are not just limited to E-tailers. You can buy stocks at 50% off too. Here are two stocks to buy now.

The One Stock I Like in this Market(The 5 Minute Wrapup)

Oct 10, 2019

There are rare periods in markets when you get good quality stocks at attractive valuations. Is this one such period?

5 Smart Money Stocks to Profit from the Market Rebound(The 5 Minute Wrapup)

Oct 11, 2019

Now is the time to put money in these 5 stocks to take advantage of the recovery in the economy and the markets.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2020
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

INDOCO REMEDIES SHARE PRICE


Oct 22, 2019 (Close)

TRACK INDOCO REMEDIES

  • Track your investment in INDOCO REMEDIES with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON INDOCO REMEDIES

INDOCO REMEDIES 5-YR ANALYSIS

COMPARE INDOCO REMEDIES WITH

MARKET STATS